Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 20.24
-0.75 (-3.57%)
May 12, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -20.23 | -22.51 | -18.09 | -70.96 | 594.25 | 678.29 |
Depreciation & Amortization | 150.03 | 150.03 | 138.01 | 157.38 | 122.1 | 55.28 |
Other Amortization | 54.16 | 54.16 | 75.31 | 78.26 | 94.83 | 27.92 |
Loss (Gain) From Sale of Assets | 0.29 | 0.29 | 2.1 | -5.67 | 0.22 | -0.01 |
Asset Writedown & Restructuring Costs | -14.16 | -14.16 | 1.8 | 1.73 | 236.85 | 2.35 |
Loss (Gain) From Sale of Investments | -5.14 | -5.14 | -59.9 | -50.92 | -88.02 | -29.81 |
Provision & Write-off of Bad Debts | - | - | 20.26 | -7.27 | 91.68 | 12.08 |
Other Operating Activities | 12.37 | 38.12 | 57.09 | 165.4 | 333.07 | 46.61 |
Change in Accounts Receivable | 22.78 | 22.78 | -188.25 | 534.67 | -682.89 | -133.2 |
Change in Inventory | -19.55 | -19.55 | -39.04 | -124.37 | -403.82 | -148.94 |
Change in Accounts Payable | 59.82 | 59.82 | -13 | -511.13 | 464.58 | 113.78 |
Change in Other Net Operating Assets | -9.88 | -9.88 | 53.56 | 25.28 | 7.37 | 7.47 |
Operating Cash Flow | 209.68 | 233.16 | -9.68 | 152.99 | 735.17 | 616.8 |
Operating Cash Flow Growth | 1148.23% | - | - | -79.19% | 19.19% | -23.24% |
Capital Expenditures | -41.82 | -47.39 | -74.9 | -232.9 | -962.86 | -261.96 |
Sale of Property, Plant & Equipment | 3.17 | 3.17 | 2.47 | 13.48 | 15.59 | 2.73 |
Cash Acquisitions | - | - | - | - | -117.93 | - |
Investment in Securities | 55.71 | -339.38 | 395.03 | -726.65 | 51.07 | -1,195 |
Other Investing Activities | 56.67 | 63.57 | 52.6 | 45.42 | 61.7 | 26.15 |
Investing Cash Flow | 73.72 | -320.03 | 375.21 | -900.65 | -952.44 | -1,428 |
Short-Term Debt Issued | - | - | 1,105 | 1,461 | 372 | - |
Long-Term Debt Issued | - | 919.39 | 0.02 | 0.56 | - | - |
Total Debt Issued | 1,225 | 919.39 | 1,105 | 1,462 | 372 | - |
Short-Term Debt Repaid | - | - | -1,723 | -638.79 | -156.41 | -39.56 |
Long-Term Debt Repaid | - | -941.36 | - | - | - | - |
Total Debt Repaid | -1,471 | -941.36 | -1,723 | -638.79 | -156.41 | -39.56 |
Net Debt Issued (Repaid) | -245.78 | -21.96 | -618.8 | 822.77 | 215.59 | -39.56 |
Issuance of Common Stock | - | - | 38.5 | - | - | 2,129 |
Repurchase of Common Stock | - | - | -104.4 | -20.01 | - | - |
Common Dividends Paid | -77.09 | -77.46 | -80.36 | -533.33 | -132.24 | -4.45 |
Other Financing Activities | -5.76 | -42.62 | -21.21 | -19.63 | -4.3 | -15.2 |
Financing Cash Flow | -328.64 | -142.05 | -786.27 | 249.8 | 79.05 | 2,070 |
Foreign Exchange Rate Adjustments | -1.34 | 2.94 | -4.24 | 1.46 | 5.04 | -2.32 |
Net Cash Flow | -46.58 | -225.98 | -424.98 | -496.4 | -133.18 | 1,256 |
Free Cash Flow | 167.86 | 185.77 | -84.58 | -79.91 | -227.69 | 354.84 |
Free Cash Flow Growth | - | - | - | - | - | -45.49% |
Free Cash Flow Margin | 11.88% | 13.48% | -6.14% | -6.21% | -6.38% | 18.99% |
Free Cash Flow Per Share | 0.40 | 0.45 | -0.23 | -0.20 | -0.57 | 0.98 |
Cash Income Tax Paid | 87.44 | 61.04 | 61.14 | 99.76 | 146.72 | 175.67 |
Levered Free Cash Flow | 243.14 | 227.86 | -105.83 | -102.16 | -451.34 | 181.59 |
Unlevered Free Cash Flow | 243.14 | 227.86 | -88.79 | -80.25 | -443.54 | 184 |
Change in Working Capital | 32.36 | 32.36 | -226.25 | -114.95 | -649.81 | -175.9 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.